74 related articles for article (PubMed ID: 3991742)
1. Antibody-complement killing of neuroblastoma cells.
Gee AP; Van Hilten J; Graham-Pole J; Boyle MD
Prog Clin Biol Res; 1985; 175():471-83. PubMed ID: 3991742
[No Abstract] [Full Text] [Related]
2. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
3. Variables affecting the killing of cultured human neuroblastoma cells with monoclonal antibody and complement.
Duerst RE; Ryan DH; Frantz CN
Cancer Res; 1986 Jul; 46(7):3420-5. PubMed ID: 3708574
[TBL] [Abstract][Full Text] [Related]
4. [Cyto-destruction of leukemic blasts in vitro using a monoclonal antibody and complement].
Pérez-Oteyza J; Brieva JA; Odriozola J; Bootello A; Navarro JL
Sangre (Barc); 1986; 31(5):587-92. PubMed ID: 2949378
[No Abstract] [Full Text] [Related]
5. Distribution of natural antibody against human neuroblastoma among children with or without neuroblastoma.
Fukuda M; Nozaki C; Ishiguro Y; Horibe K
Med Pediatr Oncol; 2001 Jan; 36(1):147-8. PubMed ID: 11464870
[TBL] [Abstract][Full Text] [Related]
6. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
7. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells.
Barker E; Reisfeld RA
Cancer Res; 1993 Jan; 53(2):362-7. PubMed ID: 8417829
[TBL] [Abstract][Full Text] [Related]
8. Multiple reactivities of cytotoxic monoclonal antibodies against pancreatic islet cells.
Suzuki M; Sharma B; Waldeck N; Charles MA
Diabetes Res; 1984 Nov; 1(4):179-81. PubMed ID: 6397292
[TBL] [Abstract][Full Text] [Related]
9. Antibody and complement-mediated cytotoxicity for bovine parainfluenza-3 virus-infected cells.
Hussain A; Mohanty SB
Am J Vet Res; 1984 Jun; 45(6):1219-21. PubMed ID: 6331235
[TBL] [Abstract][Full Text] [Related]
10. Antibody- and complement-mediated cytolysis against duck-enteritis-virus-infected cells.
Lam KM
Avian Dis; 1984; 28(4):1125-9. PubMed ID: 6525133
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermia enhancement of antibody-complement cytotoxicity for human colon tumor cells.
Tompkins WA; Rama Rao GV; Pantasatos P; Cain CA
J Natl Cancer Inst; 1981 Mar; 66(3):453-9. PubMed ID: 6937702
[TBL] [Abstract][Full Text] [Related]
12. Cloning of a human antibody directed against human neuroblastoma cells and specific for human translation elongation factor 1alpha.
Schilbach K; Kreyenberg H; Geiselhart A; Niethammer D; Handgretinger R
Tissue Antigens; 2004 Feb; 63(2):122-31. PubMed ID: 14705983
[TBL] [Abstract][Full Text] [Related]
13. [Drug targeting with allogeneic IgG in patients with disseminated neuroblastoma].
Melino G; Hobbs JR; Forrest DM; Castello MA
Clin Ter; 1984 Aug; 110(3):203-8. PubMed ID: 6237859
[No Abstract] [Full Text] [Related]
14. Development of neuroblastoma monoclonal antibodies for potential utilization in diagnosis and therapy.
Cheung NK; Saarinen U; Neely J; Miraldi F; Strandjord S; Warkentin P; Coccia P
Prog Clin Biol Res; 1985; 175():501-5. PubMed ID: 3991743
[No Abstract] [Full Text] [Related]
15. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
16. Humoral cytotoxicity in human renal cell carcinoma.
Hakala TR; Castro AE; Elliott AY; Fraley EE
Invest Urol; 1974 Mar; 11(5):405-10. PubMed ID: 4592928
[No Abstract] [Full Text] [Related]
17. Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts.
Ward RH; Lachmann PJ
Immunology; 1985 Sep; 56(1):179-88. PubMed ID: 4043993
[TBL] [Abstract][Full Text] [Related]
18. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
19. Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture.
Bloom ET
Cancer Res; 1972 May; 32(5):960-7. PubMed ID: 4502173
[No Abstract] [Full Text] [Related]
20. Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
Ishibashi M; Matsuda M; Osafune M; Nakano E; Fujioka H; Takaha M; Sonoda T; Kotake T; Watanabe S
Hinyokika Kiyo; 1983 Feb; 29(2):121-9. PubMed ID: 6677115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
